Cervical Cancer and the HPV Vaccine: A Controversial Review
Cervical cancer ranks as the fourth most prevalent cancer among women globally, claiming around 350,000 lives each year. Thankfully, for nearly two decades, the HPV vaccine has offered a straightforward and cost-effective method of prevention. Research indicates that girls vaccinated before turning 16 are about 80 percent less likely to later develop cervical cancer.
However, under the direction of Health and Human Services Secretary Robert F. Kennedy Jr., the CDC’s Advisory Committee on Immunization Practices (ACIP) has announced plans for a “comprehensive review” of the HPV vaccine. They’re looking into its efficacy, safety, and the specific phrasing around the age recommendations for routine vaccination, as well as drafting new policy suggestions.
Kennedy, who established an anti-vaccine non-profit organization known as Children’s Health Defense, has publicly criticized the HPV vaccine. In 2021, he labeled the Gardasil vaccine “dangerous and defective,” falsely asserting that it increases the risk of cervical cancer. Previously, he received referral fees from a law firm, Wisner Baum, which is actively suing Merck over allegations regarding the HPV vaccine. Although Kennedy has attempted to distance himself from the firm, he has since passed his financial interest to his son.
Just last month, a group of senators, including Edward Markey, Elizabeth Warren, Richard Blumenthal, and Angela Alsobrooks, expressed their concerns in a letter directed at Kennedy and Attorney General Pam Bondi. They urged Kennedy to step back from any involvement with vaccine injury compensation, raising alarms about potential conflicts of interest linked to his family’s financial stake in ongoing vaccine litigation.
The legislators pointed out the dangers of an opaque overhaul of vaccine courts, emphasizing that the scientific community largely agrees the HPV vaccine shouldn’t undergo any additional scrutiny. Dr. Melissa Simon, an obstetrician-gynecologist at Northwestern Medicine, criticized the review process as ideologically driven rather than based on new scientific findings, suggesting it undermines genuine concern for women’s health.
Since its debut in 2006, the HPV vaccine has faced stigma, primarily due to its association with sexual activity. It’s important to note that between 70 to 80 percent of sexually active individuals will likely contract the HPV virus at some point in their lives. While most strains are harmless, certain types are linked to various cancers, including cervical cancer. The Gardasil 9 formulation protects against several cancer-causing HPV types.
Helen Bedford, a professor at University College London, noted that the vaccine has historically encountered stigma because it addresses a sexually transmitted infection, causing some parents to hesitate about vaccinating their young daughters. Although many people clear the virus without ever realizing it, for some, HPV can remain dormant and possibly lead to cancer.
This raises a critical concern: lower vaccination rates could lead to increased cervical cancer cases. While the ACIP committee works on restructuring the age recommendations, established guidelines advocate for vaccination before age 15, ideally starting around age 11 or 12. In the UK, the vaccination is generally administered to adolescents aged 12 to 13 through school programs.
Bedford remarked that although reviewing vaccination programs is beneficial, any changes should not compromise overall uptake rates, which have dipped since the pandemic when schools were closed. However, catch-up vaccinations are possible for older adolescents.
The ACIP plans to revisit the HPV vaccine’s safety and effectiveness, yet recent data indicates that the vaccine is highly effective. A recent modeling study revealed that vaccinated individuals between ages 12 and 24 may only need cervical cancer screening every 15 to 25 years, suggesting the vaccine’s efficacy could reduce the frequency of screenings.
A Cochrane review published in November 2025 reaffirmed the vaccine’s effectiveness, particularly for younger individuals pre-exposure to HPV, stating no significant safety concerns. Notably, a study from Public Health Scotland indicated no cervical cancer cases in fully vaccinated women who received the shot between ages 12 and 13 since 2008.
Under the revised childhood vaccine schedule, the CDC now recommends a single dose of the HPV vaccine, supported by emerging data. Medical professionals agree that one dose suffices for adolescents, though those who are older or immunocompromised might still need two to three doses for optimal protection.
Kennedy’s actions have cast a shadow on established scientific guidelines, raising concerns that the American public may not benefit from rigorous scientific research aimed at promoting health. Bedford expressed alarm at how other countries, looking to the U.S. for vaccine program guidance, may perceive these shifts, especially regarding the well-documented value of the HPV vaccine in cancer prevention.
